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ABSTRACT
Objective To compare performance of multimarker algorithm, risk proﬁles and their sequential application in
prediction of preeclampsia and determining potential intervention targets.
Study Design Maternal characteristics, ultrasound variables and serum biomarkers were collected prospectively at
ﬁrst trimester. Univariate analysis identiﬁed preeclampsia associated variables followed by logistic regression analysis
to determine the prediction rule. Combined characteristics of the cardiovascular, metabolic and the personal risk
factors were compared to the multimarker algorithm and the sequential application of both methods.
Results Out of 2433 women, 108 developed preeclampsia (4.4%). Probability scores considering nulliparity, prior
preeclampsia, body mass index, diastolic blood pressure and placental growth factor had an area under the receiver
operating characteristic curve 0.784 (95% CI = 0.721–0.847). While the multimarker algorithm had the lowest false
negative rate, sequential application of cardiovascular and metabolic risk proﬁles in screen positives reduced false
positives by 26% and identiﬁed blood pressure and metabolic risk in 49/54 (91%) women with subsequent
preeclampsia as treatable risk factors.
Conclusion Sequential application of a multimarker algorithm followed by determination of treatable risk factors in
screen positive women is the optimal approach for ﬁrst trimester preeclampsia prediction and identiﬁcation of
women that may beneﬁt from targeted metabolic or cardiovascular treatment. © 2015 John Wiley & Sons, Ltd.
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INTRODUCTION
Pre-eclampsia (PE) is a multisystem disorder that complicates
2–7% of all pregnancies and is themost important contributor to
both adverse maternal and fetal outcomes.1,2 While abnormal
placentation is a major factor in the pathophysiology of PE it
has been long recognized that there are multiple contributors
that determine a woman’s risk to develop this complication.3,4
Evidence has been increasingly accumulated that prevention is
most effective if initiated by the second trimester thereby
directing efforts to identify methods that can predict PE risk
in the ﬁrst trimester.4–7 This research has resulted in the
development of several prediction rules that incorporate
multiple risk factors to derive individualized probabilities for
PE. The potential disadvantages of ﬁrst trimester prediction rules
include low positive predictive values (PPVs), concerns about
their external validity and the inability to determine potential
treatment targets for prevention.4,8
Previous studies have linked the development of PE to distinct
risk proﬁles in women. These include the cardiovascular proﬁle
deﬁned by hypertension or latent hypertension9–11; the
metabolic proﬁle deﬁned by WHO criteria12,13 and the
thrombotic risk proﬁle.14,15 A recent study demonstrated that at
least one of these risk proﬁles is present in almost 80% of women
that developed PE.16 Moreover, almost all reported ﬁrst trimester
PE screening algorithms utilize variables that reﬂect one of these
three risk proﬁles.4 Accordingly, ﬁrst trimester prediction of PE
by risk proﬁles alone may be as accurate as utilizing more
complex multimarker prediction rules and may have the added
advantage in identifying treatable risk factors. Thus, it was the
aim of this study to compare the predictive performance of risk
proﬁles alone, the multimarker prediction rule and their
sequential application when applied to the same prospectively
enrolled group of women.
MATERIALS AND METHODS
This is a secondary analysis of a prospective, observational
study with the aim of developing a ﬁrst trimester predictive
model for PE.17 Women presenting with singleton gestation
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at 9–14weeks were enrolled by informed written consent. A
questionnaire was utilized to ascertain relevant medical history,
and a standardized trans-abdominal ultrasound examination
was performed to conﬁrm gestational age, measure the fetal
crown–rump length and perform uterine artery Dopplers to
measure the Pulsatility Index. On maternal examination the
weight (in kg), height (in cm) and body mass index (BMI,
kg/m2) were measured on regularly calibrated equipment. Blood
pressure measurements (BP, mmHg) were taken using the
Dinamap Pro 1000 V3 (GE Medical Systems, Milwaukee, WI)
automated sphygmomanometer, with a cuff size appropriate for
maternal arm circumference. Sphygmomanometer calibration
occurred every 6months in accordance with the Association
for the Advancement of Medical Instrumentation guidelines.
Maternal blood samples obtained by occlusive venipuncture were
analyzed for serum concentration of pregnancy-associated
protein-A (PAPP-A), free beta human chorionic gonadotrophin
(free β-HCG) and placental growth factor (PlGF). Pregnancy
outcome was ascertained by study personnel and veriﬁed by
source documentation.
PE was deﬁned as new-onset or worsening proteinuria and
systolic blood pressure ≥140mmHg and/or diastolic blood
pressure ≥90mmHg on two separate occasions 6 or more
hours apart after 20weeks of gestation. PE superimposed on
chronic hypertension was deﬁned as worsening BP and
increasing proteinuria after 20weeks of gestation. Early PE
was deﬁned as PE requiring delivery <34weeks and late PE
deﬁned as PE requiring delivery ≥34weeks of gestation. For this
analysis we excluded patients that received aspirin prior to
16weeks’ gestation and patient with prothrombotic risk
proﬁles receiving heparin for prevention of PE as they were
already recognized at risk and treated accordingly.
Univariate analysis was performed to identify statistically
signiﬁcant individual factors that were associated with
subsequent development of PE. Relevant key factors that were
found statistically signiﬁcant on the univariate analysis were
subsequently stratiﬁed as cardiovascular or metabolic or
personal risk modiﬁers. Continuous variables were
transformed to categorical ones using receiver operator
characteristics (ROC) statistics with Youden’s Index as cut off
values. Women were then assigned as positive (1) or negative
(0) for every risk proﬁle based on the relevant key factors. Next,
we utilized all signiﬁcant key variables together in logistic
regression analysis to determine the best multimarker
prediction algorithm for ﬁrst trimester prediction of PE. The
optimal probability score cut-off was determined using ROC
curve with sensitivity set at 90%. Women were assigned as
screen positive or screen negative according to above
prediction algorithm. Finally, we compared the predictive
performance of each risk proﬁle individually, the constructed
multimarker algorithm and sequential application of the two
strategies. True positive (TP), true negative (TN), false positive
(FP) and false negative (FN) were calculated as well as risk
proﬁles ability to identify treatable risk factors (cardiovascular
or metabolic) among all screened positive women.
The statistical software package SPSS 14.0 (SPSS Inc.
Chicago, IL, USA) was used for all data analyses, and a P value
of <0.05 was considered signiﬁcant.
RESULTS
Of 2433 women meeting inclusion criteria, 108 (4.4%)
developed PE, 18 of these were early-onset PE. The mean
maternal age was 29.5 ± 6.5 years (range, 18–55) and 1063
(43.7%) were nulliparous. The majority of women were of
either Caucasian or African–Americans ethnicity (43.3% and
49.8%, respectively). Prior history was signiﬁcant for chronic
hypertension (156, 6.4%), diabetes mellitus (86, 3.5%),
thrombophilia (3, 0.1%), prior PE (69, 2.8%) and prior
gestational diabetes (44, 1.8%). Mean BMI was 28.4 kg/m2,
and mean arterial BP was 83mmHg at enrollment. Delivery was
at mean gestational age of 38.8 ± 2.3weeks (range 20.6–42.6),
and the mean birth weight was 3218±601 g. One-hundred
seventy three (7.1%) women delivered infants with a birth weight
above the 90th percentile and 221 (9.1%) with a weight below the
10th percentile.
Table 1 presents ﬁrst trimester maternal characteristics and
clinical variables stratiﬁed by subsequent development of PE.
Women with PE were more likely to be of Hispanic ethnicity,
nulliparous, hypertensive and diabetic. They were more likely
to have a prior history of PE, and at enrollment their BPs and
BMIs were higher while PlGF (MoM) and PAPP-A values
(MoM) were lower.
Statistically signiﬁcant variables were grouped by their
corresponding risk factors, and women were categorized as
positive (1) or negative (0) accordingly. Chronic hypertension
(listed as pre-pregnancy maternal diagnosis) and a BP over
120/71.5mmHg at ﬁrst trimester (values calculated by ROC
statistics) were identiﬁed as the signiﬁcant factors deﬁning the
cardiovascular risk proﬁle. Maternal diabetes, maternal BMI
>28.7 kg/m2 or ovulation induction deﬁned the metabolic risk
proﬁle. Finally, logistic regression analysis identiﬁed nulliparity
and prior PE as the signiﬁcant personal risk modiﬁers.
The ﬁrst trimester multimarker algorithm for prediction of
PE was derived from 1258 women with available placental
biomarkers results. All variables identiﬁed as signiﬁcant in the
univariate analysis were entered into logistic regression
analysis to construct a prediction rule for PE. The ﬁnal model
included nulliparity, prior PE, BMI, diastolic BP and PlGF, and
the probability scores generated an area of 0.784 (95% CI
0.721–0.847) under the curve on ROC curve statistics (Figure 1).
A probability score of 0.021 cut-off value corresponded to 90%
sensitivity, 40% speciﬁcity, 7% PPV and 99% negative predictive
value (NPV) (Table 2).
Individually, all risk proﬁles as well as the multimarker
algorithm signiﬁcantly predicted PE (P = 0.000 for all). In the
sequential approach, risk proﬁles were applied on the
multimarker algorithm screened positive women, and only
the cardiovascular and metabolic risk proﬁles remained as
signiﬁcant risk stratiﬁers (P = 0.019 and 0.016, respectively,
Table 2). As cardiovascular and metabolic risk proﬁles have
speciﬁc treatments they were included in the sequential
approach to identify the number of women that may beneﬁt
from targeted treatment based on their risk proﬁle. Among 771
screen positive women, the algorithm identiﬁed 54 TP women
with subsequent development of PE. Applying risk proﬁles in
the sequential approach further identiﬁed 49/54 (90.1%) patients
as having risk proﬁles (cardiovascular or metabolic) that can be
R. Gabbay-Benziv et al.
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treated in an individual manner. Moreover, the multimarker
algorithm itself identiﬁed 717 women as FP. Applying risk proﬁles
identiﬁed 188/717 (26.2%) of them as FP thereby and therefore
not in need for further intervention.
DISCUSSION
First trimester screening algorithms contain a combination of
maternal, placental and biophysical variables to derive
individualized risk for PE with little guidance to the treatment
that is most appropriate to prevent disease.4,18 As PE is more
frequent in women with a deﬁned set of risk proﬁles with
potential treatments, we evaluated if these are of added utility
in risk stratiﬁcation. Our study demonstrates that sequential
application of a multimarker algorithm followed by risk proﬁle
categorization in screen positive women numerically provides
the best prediction of PE. This sequential approach lowered
false positive rate by over 25% and halved the false negative
rate. Moreover, risk proﬁles identiﬁed management of
cardiovascular or metabolic risk factors as potential treatment
goals in over 90% of women that subsequently developed PE.
Table 1 First trimester maternal characteristics and clinical measurements stratiﬁed by subsequent development of pre-eclampsia
Maternal characteristic and clinical variables Developed PE N = 108 Rest of cohort N = 2325 P value
Maternal age (years), mean ± SD 28.7 ± 7.2 29.6 ± 6.5 0.158
Nulliparity N (%) 66 (61.1) 997 (42.9) 0.000
Smoking N (%) 11 (10.2) 228 (9.8) 0.869
Ethnicity N (%)
White 38 (35.2) 1016 (43.7) 0.091
African–American 62 (57.4) 1150 (49.5) 0.116
South Asian 3 (2.8) 89 (3.8) 0.797
Hispanic 4 (3.7) 27 (1.2) 0.046
Others 1 (0.9) 43 (1.8) 0.721
History of hypertension N (%) 24 (22.2) 132 (5.7) 0.000
History of diabetes N (%) 14 (13) 72 (3.1) 0.000
History of nephropathy N (%) 1 (0.9) 1 (0.0) 0.087
History of thrombophilia N (%) 0 (0) 3 (0.1) 0.873
History of PE N (%) 12 (11.1) 57 (2.5) 0.000
History of gestational diabetes N (%) 2 (1.9) 42 (1.8) 0.590
Ovulation induction N (%) 2 (1.9) 14 (0.6) 0.157
First trimester BMI (kg/m2), mean ± SD 31.0 ± 9.2 28.2 ± 7.2 0.002
Obesity level N (%)
<20 kg/m2 6 (5.6) 138 (5.9)
20–25 kg/m2 29 (26.9) 769 (33.1)
25–30 kg/m2 23 (21.3) 354 (15.2)
30–35 kg/m2 15 (13.9) 235 (10.1)
35–40 kg/m2 15 (13.9) 162 (7)
≥40 kg/m2 20 (18.5) 667 (28.7) 0.008
First trimester SBP N (%)
<120 mmHg 35 (32.4) 1605 (69)
120–140 mmHg 60 (55.6) 655 (28.2)
≥140 mmHg 13 (12) 65 (2.8) 0.000
First trimester DBP
<80 mmHg 84 (77.8) 2166 (93.2)
80–90 mmHg 18 (16.7) 143 (6.2)
≥90 mmHg 6 (5.6) 16 (0.7) 0.000
MAP (mmHg), mean ± SD 92 ± 10 83 ± 8 0.000
PAPP-A (MoM), mean ± SD 1.0 ± 0.7 1.2 ± 0.7 0.000
PlGF (MoM), mean ± SD 0.9 ± 0.4 1.1 ± 1.2 0.004
Mean UtA PIs (MoM), mean ± SD 1.1 ± 0.4 1.1 ± 0.4 0.339
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PAPP-A, placental associated plasma protein A; HCG, human chorionic gonadotrophin;
PlGF, placental growth factor; UtA PI, uterine artery pulsatility index; MoM, multiple of medians; MAP, mean arterial blood pressure.
Multimarker algorithm or risk proﬁles for prediction of preeclampsia
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Previous studies have shown that multimarker algorithms as
well as individual risk proﬁles are effective in identifying
women at risk for PE.17,19–25 The variable prevalence of
cardiovascular, metabolic and prothrombotic risk proﬁles
across populations appears to be a limiter to their generalized
screening application.8,16,26,27 Multimarker algorithms on the
other hand also incorporate placental factors and through
mathematical consideration of a wider range of risk modiﬁers
are able to provide better risk stratiﬁcation in their populations
of origin.4,5,8,22,26 Presently, women identiﬁed at risk for PE are
offered ﬁrst trimester low-dose aspirin based on the
recommendations of the US Preventive services task force.7
However, the beneﬁts of low dose aspirin may be limited to
women with a high prevalence of cardiovascular andmetabolic
risk proﬁles and a low prevalence of prothrombotic risks.18,28
Accordingly, aspirin alone appears to address a speciﬁc risk
proﬁle if initiated by 16weeks but has limited utility as a
universal prevention for all women deﬁned at risk by different
prediction strategies.6,7 This raises the question if additional
therapies could be offered to women where a sequential
screening approach identiﬁes additional risk proﬁles.
Observations in women with polycystic ovarian syndrome
that become pregnant suggests that continuation of
Metformin is associated with reduced rates of PE which
appear to be partly mediated by accelerated normalization
of ﬁrst trimester uterine artery blood ﬂow resistance.29–32
Pravastatin inhibits sFLT-1 release in mouse models and is
currently being evaluated in two human randomized
controlled clinical trials for their safety in pregnancy and their
efﬁcacy in the prevention of PE (www.controlled-trials.com:
ISRCTN23410175 and ClinicalTrials.gov: NCT01717586).33–36
It is therefore likely that evidenced based recommendations
will become available in the near future to offer women with
a metabolic risk proﬁle identiﬁed at ﬁrst trimester sequential
PE screening risk speciﬁc preventive therapy in addition to
low dose aspirin.4 Hypertension is a key component of the
cardiovascular and metabolic risk proﬁle and accordingly
numerically the most important ﬁrst trimester contributor
to PE risk. Unfortunately, opinions regarding the optimal
treatment threshold in the ﬁrst trimester diverge strongly.
The risk for hypertensive complications increases at blood
pressures that are below the treatment threshold that is
currently recommended by most professional societies.4,37–
39 Accordingly, research to deﬁne the appropriate approach
to blood pressure in ﬁrst trimester screen positive women
for prevention of PE is urgently needed. Therefore application
of a sequential ﬁrst trimester screening approach for PE
would enable administration of risk speciﬁc therapy to
women with metabolic risks and provide a tool to deﬁne
women that are appropriate candidates for research studies
on the appropriate ﬁrst trimester initiation of blood pressure
management. We suggest a two-step screening protocol in
which a multimarker algorithm will be applied ﬁrst, in order
to detect women at risk for future PE with the highest
sensitivity, followed by individualized treatment based on
stratiﬁcation by risk proﬁles (Figure 2).
The strengths of our study lie in the large number of
prospectively enrolled patients with outcomes that were veriﬁed
with precise source documentation. The prevalence of the
individual risk proﬁles and PE allowed us to test our hypothesis.
Our data suggests that the optimal screening approach lies in the
development of sequential screening algorithm where the ﬁrst
step should be optimized to offer the highest sensitivity (for this
purpose incorporation of additional prothrombotic markers such
as serum homocysteine as well as modiﬁcation of statistical
Figure 1 Prediction performance of multimarker algorithm for ﬁrst
trimester prediction of pre-eclampsia. Area under the curve is
0.784 (95% CI 0.721–0.847)
Table 2 Prediction performance of multimarker algorithm and risk proﬁles for subsequent development of pre-eclampsia—individual
versus sequential approach
Sensitivity Speciﬁcity PPV NPV
TP TN FP FN% (95% CI) % (95% CI) % (95% CI) % (95% CI)
Cardiovascular risk proﬁle (N = 2433) 80.6 (71.8–87.5) 59.2 (57.2–61.2) 8.4 (6.8–10.3) 99 (97.7–99.1) 87 1376 949 21
Metabolic risk proﬁle (N = 2433) 60.6 (50.7–69.8) 61.9 (59.9–63.9) 6.9 (5.4–8.7) 97.1 (96.1–97.9) 66 1439 886 42
Personal risk proﬁle (N = 2433) 71.3 (61.8–79.6) 54.7 (52.7–56.8) 6.8 (5.4–8.4) 97.6 (96.6–98.4) 77 1272 1053 31
Multimarker algorithm (N = 2433) 90 (79.5–96.2) 40.2 (37.4–43.0) 7 (5.3–9) 98.8 (97.3–99.5) 54 481 717 6
Second stage sequential analysisa (N = 771) 90.7 (79.7–96.9) 26.2 (23–29.6) 8.5 (6.3–11.1) 97.4 (94.1–99.1) 49 188 529 5
PPV, positive predictive value; NPV, negative predictive value; TP, true positive; TN, true negative; FP, false positive; FN, false negative.
aSequential approach—this line refers to applying cardiovascular or metabolic risk proﬁles (treatable) only on women screened positive by the multimarker algorithm.
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approaches may prove useful4,5,16,19,21,40) and the second step will
identify the appropriate threshold for cardiovascular, metabolic
and prothrombotic risk proﬁles to trigger intervention. This is
most tangible for metabolic and prothrombotic risks and
controversial for deﬁning blood pressure treatment targets for
patients identiﬁed with cardiovascular risk in the ﬁrst trimester.
Given the prevalence and relevance of the cardiovascular risk
proﬁle in pregnancy outcome and long-term health of women,
sequential ﬁrst trimester PE screening algorithms may prove to
be critical to advance research in this area of women’s healthcare.
Nevertheless, our study has some limitations to consider: because
of their documented importance in determining the accuracy of
multimarker algorithms, we chose to include placental biomarkers
results in our study. As these were only available for a subset of
study participants this limited our sample size for the sequential
prediction approach. However, we chose to use the entire cohort
in order to obtain better accuracy for the individual risk factors
in the univariate analysis. Also, this limited sample size prevented
us from splitting it to a training group and a validation group. This
will need to be done in future greater samples. Moreover, the
exclusion of women receiving aspirin and anticoagulation further
skewed our population towards women with cardiovascular and
metabolic risk proﬁles, which are prevalent in the environment
where this study was conducted. Finally, we pre-determined that
for the sequential approach the multimarker algorithm was
applied before the risk proﬁles. This approach was chosen based
on a clinical model where women that are screened positive would
be further evaluated for speciﬁc treatment.
In summary, we present a new sequential approach for ﬁrst
trimester prediction of PE using a multimarker algorithm
followed by application of risk proﬁles. This approach correctly
predicts the highest proportion of women that develop PE and
has the advantage of identifying potential treatment targets to
prevent PE. This sequential screening approach may prove
beneﬁcial to determine women who should receive
management for metabolic risks and to clarify appropriate
management of cardiovascular risks.
WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• First trimester prediction of preeclampsia is feasible by multimarker
algorithms incorporating maternal characteristics, ultrasound
variables and serum biomarkers or by stratifying women based on
their risk proﬁle: mainly thrombotic, cardiovascular or metabolic.
• The optimal method of prediction is still unknown.
• All women at high risk for developing preeclampsia are treated the
same by low dose aspirin.
WHAT DOES THIS STUDY ADD?
• Combination of multimarker algorithm followed by further
stratiﬁcation of the screen positive women by risk proﬁles has two
advantages: (a) lowering false positive rate, therefore preventing
unnecessary treatment and (b) enabling the potential for targeted
treatment based on the individual risk proﬁle (i.e. metabolic,
cardiovascular or thrombotic).
REFERENCES
1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:
785–99.
2. American College of Obstetricians and Gynecologists. Diagnosis of
Management of Pre-Eclampsia and Eclampsia, ACOG Practice Bulletin
#33. American College of Obstetricians and Gynecologists:
Washington, DC; 2002.
3. Chesley LC. History and epidemiology of preeclampsia–eclampsia. Clin
Obstet Gynecol 1984;27:801–20.
4. Baschat AA. First trimester screening for pre-eclampsia: moving from
personalized risk prediction to prevention. Ultrasound Obstet Gynecol
2015;45:119–29.
5. Nicolaides KH. Turning the pyramid of prenatal care. Fetal Diagn Ther
2011;29:183–96.
6. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and
intrauterine growth restriction with aspirin started in early pregnancy: a
meta-analysis. Obstet Gynecol 2010;116:402–14.
Figure 2 Suggested optimal approach for ﬁrst trimester prediction of pre-eclampsia
Multimarker algorithm or risk proﬁles for prediction of preeclampsia
Prenatal Diagnosis 2015, 35, 1–6 © 2015 John Wiley & Sons, Ltd.
7. Levefre ML. Low-dose aspirin use for the prevention of morbidity and
mortality from pre-eclampsia: U.S. Preventive Services Task Force
Recommendation Statement. Ann Intern Med 2014;161:819–26.
8. Oliveira N,Magder LS, Blitzer MG, Baschat AA. First-trimester prediction
of pre-eclampsia: external validity of algorithms in a prospectively
enrolled cohort. Ultrasound Obstet Gynecol 2014;44:279–85.
9. Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive
disorders in pregnancy and subsequently measured cardiovascular risk
factors. Obstet Gynecol 2009;114:961–70.
10. Spaanderman M, Ekhart T, van Eyck J, et al. Preeclampsia and
maladaptation to pregnancy: a role for atrial natriuretic peptide? Kidney
Int 2001;60:1397–406.
11. Zandstra M, Stekkinger E, van der Vlugt MJ, et al. Cardiac diastolic
dysfunction and metabolic syndrome in young women after placental
syndrome. Obstet Gynecol 2010;115:101–8.
12. Forest JC, Girouard J, Masse J, et al. Early occurrence of metabolic
syndrome after hypertension in pregnancy. Obstet Gynecol
2005;105:1373–80.
13. Stekkinger E, Zandstra M, Peeters LL, Spaanderman ME. Early-onset
preeclampsia and the prevalence of postpartum metabolic syndrome.
Obstet Gynecol 2009;114:1076–84.
14. Dekker GA, de Vries JI, Doelitzsch PM, et al. Underlying disorders
associated with severe early-onset preeclampsia. Am J Obstet Gynecol
1995;173:1042–8.
15. Van Pampus MG, Dekker GA, Wolf H, et al. High prevalence of
hemostatic abnormalities in women with a history of severe
preeclampsia. Am J Obstet Gynecol 1999;180:1146–50.
16. Scholten RR, Hopman MT, Sweep FC, et al. Co-occurrence of
cardiovascular and prothrombotic risk factors in women with a history
of preeclampsia. Obstet Gynecol 2013;12:97–105.
17. Baschat AA, Magder LS, Doyle LE, et al. Prediction of preeclampsia
utilizing the ﬁrst trimester screening examination. Am J Obstet Gynecol
2014;211:514.e1–7.
18. Sibai B. First-trimester screening with combined maternal clinical
factors, biophysical and biomarkers to predict preterm pre-eclampsia
and hypertensive disorders: are they ready for clinical use? BJOG
2015;122:282–3.
19. Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early
screening for preeclampsia by biophysical and biochemical markers.
Fetal Diagn Ther 2013;33:8–15.
20. Audibert F, Boucoiran I, An N, et al. Screening for preeclampsia using
ﬁrst-trimester serum markers and uterine artery Doppler in nulliparous
women. Am J Obstet Gynecol 2010;203:383.e1–8.
21. Poon L, Stratieva V, Piras S, et al. Hypertensive disorders in pregnancy:
combined screening by uterine artery Doppler, blood pressure and
serum PAPP-A at 11–13 weeks. Prenat Diagn 2010;30:216–23.
22. Park F, Leung C, Poon L, et al. Clinical evaluation of a ﬁrst trimester
algorithm predicting the risk of hypertensive disease of pregnancy. Aust
N Z J Obstet Gynaecol 2013;53:532–9.
23. Scazzocchio E, Figueras F, Crispi F, et al. Performance of a ﬁrst-
trimester screening of preeclampsia in a routine care low-risk setting.
Am J Obstet Gynecol 2013;208:203e.1–10.
24. Odibo A, Zhong Y, Goetzinger K, et al. First-trimester placental protein-
13, PAPP-A, uterine artery Doppler and maternal characteristics in the
prediction of pre-eclampsia. Placenta 2011;32:598–02.
25. Kuc S, Koster M, Franx A, et al. Maternal characteristics. Mean arterial
pressure and serum markers in early prediction of preeclampsia. Plos
ONE 2013;8e63546.
26. Oliveira N, Doyle LE, Atlas RO, et al. External validity of ﬁrst-trimester
algorithms in the prediction of pre-eclampsia disease severity.
Ultrasound Obstet Gynecol 2014;44:286–92.
27. Grundy SM, Brewer HB Jr, Cleeman JI, et al. American Heart
Association; National Heart, Lung, and Blood Institute. Deﬁnition of
metabolic syndrome: report of the National Heart, Lung, and Blood
Institute/American Heart Association conference on scientiﬁc issues
related to deﬁnition. Circulation 2004;109:433–8.
28. Villa PM, Kajantie E, Räikkönen K, et al. Aspirin in the prevention of
pre-eclampsia in high-risk women: a randomized placebo-controlled
PREDO Trial and a meta-analysis of randomized trials. BJOG
2013;120:64–74.
29. Zheng J, Shan PF, Gu W. The efﬁcacy of metformin in pregnant women
with polycystic ovary syndrome: a meta-analysis of clinical trials.
J Endocrinol Invest 2013;36:797–802.
30. De Leo V, Musacchio MC, Piomboni P, et al. The administration of
metformin during pregnancy reduces polycystic ovary syndrome
related gestational complications. Eur J Obstet Gynecol Reprod Biol
2011;157:63–6.
31. Nawaz FH, Khalid R, Naru T, Rizvi J. Does continuous use of metformin
throughout pregnancy improve pregnancy outcomes in women with
polycystic ovarian syndrome? J Obstet Gynaecol Res 2008;34:832–7.
32. Salvesen KA, Vanky E, Carlsen SM. Metformin treatment in pregnant
women with polycystic ovary syndrome—is reduced complication rate
mediated by changes in the uteroplacental circulation? Ultrasound
Obstet Gynecol 2007;29:433–7.
33. Fox KA, Longo M, Tamayo E, et al. Effects of pravastatin on mediators
of vascular function in a mouse model of soluble Fms-like tyrosine
kinase-1-induced preeclampsia. Am J Obstet Gynecol 2011;205:
e1-366–e365.
34. Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental
growth factor and ameliorates preeclampsia in a mouse model. Proc
Natl Acad Sci USA 2011;108:1451–5.
35. Bauer AJ, Banek CT, Needham K, et al. Pravastatin attenuates
hypertension, oxidative stress, and angiogenic imbalance in rat model
of placental ischemia-induced hypertension. Hypertension
2013;61:1103–10.
36. Saad AF, Kechichian T, Yin H, et al. Effects of pravastatin on angiogenic
and placental hypoxic imbalance in a mouse model of preeclampsia.
Reprod Sci 2014;21:138–45.
37. Gaillard R, Bakker R, Willemsen SP, et al. Blood pressure tracking during
pregnancy and the risk of gestational hypertensive disorders: the
Generation R Study. Eur Heart J 2011;32:3088–97.
38. Gillon TE, Pels A, von Dadelszen P, et al. Hypertensive disorders of
pregnancy: a systematic review of international clinical practice
guidelines. PLoS One 2014;9e113715.
39. Scantlebury DC, Schwartz GL, Acquah LA, et al. The treatment of
hypertension during pregnancy: when should blood pressure
medications be started? Curr Cardiol Rep 2013;15:412.
40. Cotter AM, Molloy AM, Scott JM, Daly SF. Elevated plasma
homocysteine in early pregnancy: a risk factor for the development of
severe pre-eclampsia. Am J Obstet Gynecol 2001;185:781–5.
R. Gabbay-Benziv et al.
Prenatal Diagnosis 2015, 35, 1–6 © 2015 John Wiley & Sons, Ltd.
